| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients
|
Morabito, Alessandro
|
|
2017
|
108 |
C |
p. 15-21
|
artikel
|
| 2 |
An interesting observation from our experiences with circulating tumour cells
|
Lim, Kok H.
|
|
2017
|
108 |
C |
p. 247-249
|
artikel
|
| 3 |
A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib
|
Moran, Teresa
|
|
2017
|
108 |
C |
p. 154-160
|
artikel
|
| 4 |
A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer
|
Harris, Jeremy P.
|
|
2017
|
108 |
C |
p. 173-182
|
artikel
|
| 5 |
A randomized controlled trial comparing indwelling pleural catheters with talc pleurodesis (NVALT-14)
|
Boshuizen, R.C.
|
|
2017
|
108 |
C |
p. 9-14
|
artikel
|
| 6 |
A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer
|
Wehler, Thomas
|
|
2017
|
108 |
C |
p. 212-216
|
artikel
|
| 7 |
Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy
|
Koshy, Matthew
|
|
2017
|
108 |
C |
p. 222-227
|
artikel
|
| 8 |
CD52, CD22, CD26, EG5 and IGF-1R expression in thymic malignancies
|
Remon, J.
|
|
2017
|
108 |
C |
p. 168-172
|
artikel
|
| 9 |
Contents
|
|
|
2017
|
108 |
C |
p. iv-vii
|
artikel
|
| 10 |
Contrasting temporal trends in lung cancer incidence by socioeconomic status among women in New South Wales, Australia, 1985–2009
|
Yu, Xue Qin
|
|
2017
|
108 |
C |
p. 55-61
|
artikel
|
| 11 |
Corrigendum to “Prognosis in advanced lung cancer – A prospective study examining key clinicopathological factors” [Lung Cancer 88 (2015) 304–309]
|
Simmons, Claribel P.
|
|
2017
|
108 |
C |
p. 256
|
artikel
|
| 12 |
Cost-effectiveness of implementing computed tomography screening for lung cancer in Taiwan
|
Yang, Szu-Chun
|
|
2017
|
108 |
C |
p. 183-191
|
artikel
|
| 13 |
Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature
|
Ruiz-Bañobre, Juan
|
|
2017
|
108 |
C |
p. 217-221
|
artikel
|
| 14 |
Economic burden of clinical trials in lung cancer in a German Comprehensive Cancer Center
|
Kron, F.
|
|
2017
|
108 |
C |
p. 134-139
|
artikel
|
| 15 |
Editorial Board
|
|
|
2017
|
108 |
C |
p. iii
|
artikel
|
| 16 |
EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib
|
Ibrahim, Uroosa
|
|
2017
|
108 |
C |
p. 45-47
|
artikel
|
| 17 |
Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib
|
Ou, Sai-Hong Ignatius
|
|
2017
|
108 |
C |
p. 228-231
|
artikel
|
| 18 |
Erratum to “Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer” [Lung Cancer 76 (1) (2012) 32–38]
|
Tanaka, Norimitsu
|
|
2017
|
108 |
C |
p. 254-255
|
artikel
|
| 19 |
EUS-B-FNA vs conventional EUS-FNA for left adrenal gland analysis in lung cancer patients
|
Crombag, Laurence M.M.J.
|
|
2017
|
108 |
C |
p. 38-44
|
artikel
|
| 20 |
How should “RET positive” NSCLC be treated?
|
Smit, Egbert F.
|
|
2017
|
108 |
C |
p. 250-251
|
artikel
|
| 21 |
Imaging features of TSCT predict the classification of pulmonary preinvasive lesion, minimally and invasive adenocarcinoma presented as ground glass nodules
|
Liu, Yinan
|
|
2017
|
108 |
C |
p. 192-197
|
artikel
|
| 22 |
Improved survival with postoperative radiotherapy in thymic carcinoma: A propensity-matched analysis of Surveillance, Epidemiology, and End Results (SEER) database
|
Lim, Yu Jin
|
|
2017
|
108 |
C |
p. 161-167
|
artikel
|
| 23 |
Intra-Thoracic Chemo-Hyperthermia for pleural recurrence of thymoma
|
Maury, Jean Michel
|
|
2017
|
108 |
C |
p. 1-6
|
artikel
|
| 24 |
Investigation of patterns of nodal metastases in BRAF mutant lung cancer
|
McEvoy, S.H.
|
|
2017
|
108 |
C |
p. 62-65
|
artikel
|
| 25 |
LINE-1 hypomethylation is associated to specific clinico-pathological features in Stage I non-small cell lung cancer
|
Imperatori, Andrea
|
|
2017
|
108 |
C |
p. 83-89
|
artikel
|
| 26 |
Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series
|
Tchekmedyian, Nishan
|
|
2017
|
108 |
C |
p. 22-28
|
artikel
|
| 27 |
Long-lasting shrinkage in tumor mass after discontinuation of nivolumab treatment
|
Kimura, Hideharu
|
|
2017
|
108 |
C |
p. 7-8
|
artikel
|
| 28 |
Lung cancer incidence trends in California by race/ethnicity, histology, sex, and neighborhood socioeconomic status: An analysis spanning 28 years
|
Patel, Manali I.
|
|
2017
|
108 |
C |
p. 140-149
|
artikel
|
| 29 |
Mesothelioma continues to increase even 40 years after exposure – Evidence from long-term epidemiological observation
|
Świątkowska, B.
|
|
2017
|
108 |
C |
p. 121-125
|
artikel
|
| 30 |
Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non–small cell lung cancer
|
Hidaka, Noriko
|
|
2017
|
108 |
C |
p. 75-82
|
artikel
|
| 31 |
Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib
|
Patel, Suchit H.
|
|
2017
|
108 |
C |
p. 109-114
|
artikel
|
| 32 |
PD-L1 expression in neuroendocrine tumors of the lung
|
Tsuruoka, Kenjiro
|
|
2017
|
108 |
C |
p. 115-120
|
artikel
|
| 33 |
Peripheral-type small cell lung cancer is associated with better survival and higher frequency of interstitial lung disease
|
Kanaji, Nobuhiro
|
|
2017
|
108 |
C |
p. 126-133
|
artikel
|
| 34 |
Preliminary evaluation of a telephone-based smoking cessation intervention in the lung cancer screening setting: A randomized clinical trial
|
Taylor, Kathryn L.
|
|
2017
|
108 |
C |
p. 242-246
|
artikel
|
| 35 |
Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas
|
Schilsky, Juliana B.
|
|
2017
|
108 |
C |
p. 205-211
|
artikel
|
| 36 |
Prognostic impact of uncertain parietal pleural invasion at adhesion sites in non-small cell lung cancer patients
|
Mikubo, Masashi
|
|
2017
|
108 |
C |
p. 103-108
|
artikel
|
| 37 |
Quantification of growth patterns of screen-detected lung cancers: The NELSON study
|
Heuvelmans, Marjolein A.
|
|
2017
|
108 |
C |
p. 48-54
|
artikel
|
| 38 |
Randomized phase II trial of weekly dose-intensive chemotherapy or amrubicin plus cisplatin chemotherapy following induction chemoradiotherapy for limited-disease small cell lung cancer (JCOG1011)
|
Sekine, Ikuo
|
|
2017
|
108 |
C |
p. 232-237
|
artikel
|
| 39 |
Semi-automatic volumetric measurement of response to chemotherapy in lung cancer patients: How wrong are we using RECIST?
|
Greenberg, Vladislav
|
|
2017
|
108 |
C |
p. 90-95
|
artikel
|
| 40 |
Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC
|
Knebel, Franciele H.
|
|
2017
|
108 |
C |
p. 238-241
|
artikel
|
| 41 |
Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II study
|
Niho, Seiji
|
|
2017
|
108 |
C |
p. 66-71
|
artikel
|
| 42 |
Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient
|
Gion, Maria
|
|
2017
|
108 |
C |
p. 72-74
|
artikel
|
| 43 |
Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer
|
Zhao, Jane
|
|
2017
|
108 |
C |
p. 96-102
|
artikel
|
| 44 |
Targeted therapy in small cell lung cancer: A new era?
|
Capelletto, Enrica
|
|
2017
|
108 |
C |
p. 252-253
|
artikel
|
| 45 |
Treatment options for EGFR mutant NSCLC with CNS involvement—Can patients BLOOM with the use of next generation EGFR TKIs?
|
Tan, Chee-Seng
|
|
2017
|
108 |
C |
p. 29-37
|
artikel
|
| 46 |
Trends in treatment and relative survival among Non-Small Cell Lung Cancer patients in the Netherlands (1990–2014): Disparities between younger and older patients
|
Driessen, Elisabeth J.
|
|
2017
|
108 |
C |
p. 198-204
|
artikel
|
| 47 |
Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial
|
Slotman, Ben J.
|
|
2017
|
108 |
C |
p. 150-153
|
artikel
|
Tijdschrift beschrijving